Currently, there are 94.54M common shares owned by the public and among those 82.39M shares have been available to trade.
The company’s stock has a 5-day price change of 17.73% and 32.24% over the past three months. BHVN shares are trading 7.34% year to date (YTD), with the 12-month market performance up to 167.25% higher. It has a 12-month low price of $16.45 and touched a high of $62.21 over the same period. BHVN has an average intraday trading volume of 939.82K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 18.59%, 19.86%, and 9.50% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Biohaven Ltd (NYSE: BHVN) shares accounts for 88.15% of the company’s 94.54M shares outstanding.
It has a market capitalization of $4.34B and a beta (3y monthly) value of 4.13. The earnings-per-share (ttm) stands at -$9.16. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.63% over the week and 4.55% over the month.
Earnings per share for the fiscal year are expected to decrease by -56.99%, and 27.28% over the next financial year.
Looking at the support for the BHVN, a number of firms have released research notes about the stock. Jefferies stated their Buy rating for the stock in a research note on September 16, 2024, with the firm’s price target at $57. Bernstein coverage for the Biohaven Ltd (BHVN) stock in a research note released on September 04, 2024 offered a Outperform rating with a price target of $55. Morgan Stanley was of a view on July 24, 2024 that the stock is Overweight, while RBC Capital Mkts gave the stock Outperform rating on February 16, 2024, issuing a price target of $62. UBS on their part issued Buy rating on February 06, 2024.
